Search
02/01/2022
Validity of the Sedentary Behavior Questionnaire in European Older Adults Using English, Spanish, German and Danish Versions
Sansano-Nadal, O, Wilson, JJ, Martin-Borras, C, Brond, JC, Skjodt, M, Caserotti, P, Figuls, MRI, Blackburn, NE, Klenk, J, Rothenbacher, D, Guerra-Balic, M, Font-Farre, M, Denkinger, M, Coll-Planas, L, Deidda, M, McIntosh, E, Gine-Garriga, M, Tully, MA. Validity of the Sedentary Behavior Questionnaire in European Older Adults Using English, Spanish, German and Danish Versions. Measurement in Physical Education and Exercise Science. 2022; 26(1)DOI:10.1080/1091367X.2021.1922910. PMID:. IF:2.100(Q3/7D).
02/01/2022
Establishment and validation of surface model for biodosimetry based on gamma-H2AX foci detection
Lopez, JS, Pujol-Canadell, M, Puig, P, Ribas, M, Carrasco, P, Armengol, G, Barquinero, JF. Establishment and validation of surface model for biodosimetry based on gamma-H2AX foci detection. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2022; 98(1)DOI:10.1080/09553002.2022.1998706. PMID:34705602. IF:2.600(Q1/3D).
02/01/2022
Bilateral Marginal Corneal Infiltrates: A Novel Ocular Manifestation of DRESS Syndrome
Vela, JI, Bulnes, V, Torrell, N, Giro, M, Perich, S. Bilateral Marginal Corneal Infiltrates: A Novel Ocular Manifestation of DRESS Syndrome. OCULAR IMMUNOLOGY AND INFLAMMATION. 2022; 30(1)DOI:10.1080/09273948.2020.1797111. PMID:32816571. IF:3.300(Q2/3D).
02/01/2022
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, A, Canales, MA, Dlouhy, I, Mercadal, S, Briones, J, Garcia-Sancho, AM, Sancho, JM, Moraleda, JM, Terol, MJ, Salar, A, Palomera, L, Gardella, S, Jarque, I, Ferrer, S, Bargay, J, Lopez, A, Panizo, C, Muntanola, A, Montalban, C, Conde, E, Hernandez, MT, Soler, A, Marco, JAG, Deben, G, Marin, J, Tomas, JF. A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. LEUKEMIA & LYMPHOMA. 2022; 63(1)DOI:10.1080/10428194.2021.1971216. PMID:34459702. IF:2.600(Q3/7D).
01/01/2022
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy
Martín-Aguilar L, Lleixà C, Pascual-Goñi E, Caballero-Ávila M, Martínez-Martínez L, Díaz-Manera J, Rojas-García R, Cortés-Vicente E, Turon-Sans J, de Luna N, Suárez-Calvet X, Gallardo E, Rajabally Y, Scotton S, Jacobs BC, Baars A, Cortese A, Vegezzi E, Höftberger R, Zimprich F, Roesler C, Nobile-Orazio E, Liberatore G, Hiew FL, Martínez-Piñeiro A, Carvajal A, Piñar-Morales R, Usón-Martín M, Albertí O, López-Pérez MÁ, Márquez F, Pardo-Fernández J, Muñoz-Delgado L, Cabrera-Serrano M, Ortiz N, Bartolomé M, Duman Ö, Bril V, Segura-Chávez D, Pitarokoili K, Steen C, Illa I, Querol L. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology-Neuroimmunology & Neuroinflammation. 2022; 9(1)DOI:10.1212/NXI.0000000000001098. PMID:34728497. IF:8.800(Q1/1D).
01/01/2022
Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia
Caballero-Ávila M., Álvarez-Velasco R., Moga E., Rojas-Garcia R., Turon-Sans J., Querol L., Olivé M., Reyes-Leiva D., Illa I., Gallardo E., Cortés-Vicente E.. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. NEUROMUSCULAR DISORDERS. 2022; 32(8)DOI:10.1016/j.nmd.2022.06.006. PMID:35811274. IF:2.800(Q3/6D).
01/01/2022
Azathioprine therapy induces selective NK cell depletion and IFN-? deficiency predisposing to herpesvirus reactivation
Ingelfinger F., Sparano C., Bamert D., Reyes-Leiva D., Sethi A., Rindlisbacher L., Zwicky P., Kreutmair S., Widmer C.C., Mundt S., Cortés-Vicente E., Tugues S., Becher B., Schreiner B.. Azathioprine therapy induces selective NK cell depletion and IFN-? deficiency predisposing to herpesvirus reactivation. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2022; 151(1)DOI:10.1016/j.jaci.2022.09.010. PMID:36122787. IF:14.200(Q1/1D).
01/01/2022
Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management
Bolano-Diaz, C, Diaz-Manera, J. Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management. Therapeutics and Clinical Risk Management. 2022; 18DOI:10.2147/TCRM.S334232. PMID:36536827. IF:2.800(Q3/6D).